Technical Analysis for ACW - Actinogen Medical Ltd
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.025 | 4.17% | 0.001 |
Earnings due: Nov 15
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| Lizard Bullish | Bullish Day Trade Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 4.17% | |
| Bollinger Band Squeeze | Range Contraction | 4.17% |
| Alert | Time |
|---|---|
| Gap Up Closed | 2 days ago |
| Reversed from Up | 2 days ago |
| Gapped Up (Full) | 2 days ago |
| Rose Above Lower Bollinger Band | 2 days ago |
| Up 2% | 2 days ago |
Free Daily (Stock) Chart Reading
Actinogen Medical Ltd Description
Actinogen Medical Limited, formerly Actinogen Limited, is a clinical-stage biotechnology company. The Company focuses on the treatment of Alzheimer's disease and age-related neurodegenerative diseases. The Company is engaged in treating cognitive impairment in chronic neurodegenerative diseases through the inhibition of cortisol production. The Company's Xanamem is a drug under development for the treatment of Alzheimer's disease, which is designed to block the production of cortisol in the brain. Xanamem's mechanism of action is to block the activity of a specific enzyme in the brain, the 11B-HSD1 enzyme. It focuses on Xanamem in the clinical areas, including Diabetes-Cognitive dysfunction, Cognitive dysfunction in Parkinson's Disease, Post Traumatic Stress Disorder (PTSD), Cognitive dysfunction in schizophrenia and depression, and Cardiovascular disease-Post myocardial infarction. It focuses on Phase II XanADu efficacy and safety study with mild Alzheimer's disease patients.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Disease Diseases Safety Diabetes Psychiatric Diagnosis Psychiatry Dementia Alzheimer's Disease Parkinson Aging Associated Diseases Degenerative Disease Parkinson's Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.099 |
| 52 Week Low | 0.016 |
| Average Volume | 13,099,818 |
| 200-Day Moving Average | 0.037 |
| 50-Day Moving Average | 0.030 |
| 20-Day Moving Average | 0.026 |
| 10-Day Moving Average | 0.026 |
| Average True Range | 0.002 |
| RSI (14) | 52.61 |
| ADX | 11.96 |
| +DI | 17.814 |
| -DI | 24.292 |
| Chandelier Exit (Long, 3 ATRs) | 0.024 |
| Chandelier Exit (Short, 3 ATRs) | 0.029 |
| Upper Bollinger Bands | 0.028 |
| Lower Bollinger Band | 0.024 |
| Percent B (%b) | 0.21 |
| BandWidth | 14.559 |
| MACD Line | -0.002 |
| MACD Signal Line | -0.002 |
| MACD Histogram | 0.0002 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.027 | ||||
| Resistance 3 (R3) | 0.026 | 0.026 | 0.026 | ||
| Resistance 2 (R2) | 0.026 | 0.025 | 0.026 | 0.026 | |
| Resistance 1 (R1) | 0.025 | 0.025 | 0.026 | 0.026 | 0.026 |
| Pivot Point | 0.025 | 0.025 | 0.025 | 0.025 | 0.025 |
| Support 1 (S1) | 0.024 | 0.024 | 0.025 | 0.025 | 0.024 |
| Support 2 (S2) | 0.024 | 0.024 | 0.024 | 0.024 | |
| Support 3 (S3) | 0.023 | 0.024 | 0.024 | ||
| Support 4 (S4) | 0.024 |
